Use these links to rapidly review the document
TABLE OF CONTENTS

Table of Contents


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the Quarterly Period Ended DecemberMarch 31, 20142015

Commission file number 000-23731

LOGOLOGO


NUTRACEUTICAL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)
 87-0515089
(IRS Employer Identification No.)

1400 Kearns Boulevard, 2nd Floor, Park City, Utah
(Address of principal executive offices)

 

84060
(Address of principal executive offices)
(Zip code)

(435) 655-6106
(Registrant's telephone number, including area code)

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ý    NO o

        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ý    NO o

        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer o Accelerated filer ý Non-accelerated filer o
(Do not check if a
smaller reporting company)
 Smaller reporting company o

        Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o    NO ý

        At January 28,April 27, 2015, the registrant had 9,635,0619,561,236 shares of common stock outstanding.

   


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

INDEX

Description


 Page No. 

Part I.

 Financial Information  3 



 


Item 1.


 


Financial Statements (unaudited)


 

 


3

 



 

 

 


Condensed Consolidated Balance Sheets—DecemberMarch 31, 20142015 and September 30, 2014


 

 


3

 



 

 

 


Condensed Consolidated Statements of Operations and Comprehensive Income—Three Months and Six Months Ended DecemberMarch 31, 20142015 and 20132014


 

 


4

 



 

 

 


Condensed Consolidated Statements of Cash Flows—ThreeSix Months Ended DecemberMarch 31, 20142015 and 20132014


 

 


5

 



 

 

 


Notes to Condensed Consolidated Financial Statements


 

 


6

 



 


Item 2.


 


Management's Discussion and Analysis of Financial Condition and Results of Operations


 

 


1314

 



 


Item 3.


 


Quantitative and Qualitative Disclosures About Market Risk


 

 


2022

 



 


Item 4.


 


Controls and Procedures


 

 


2022

 


Part II.


 


Other Information


 

 


2123

 



 


Item 1.


 


Legal Proceedings


 

 


2123

 



 


Item 1A.


 


Risk Factors


 

 


2123

 



 


Item 2.


 


Unregistered Sales of Equity Securities and Use of Proceeds


 

 


2123

 



 


Item 6.


 


Exhibits


 

 


2224

 

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1.    Financial Statements

        


NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(dollars in thousands)


 December 31,
2014
 September 30,
2014(1)
  March 31,
2015
 September 30,
2014(1)
 

ASSETS

          

Current assets:

          

Cash

 $3,923 $6,232  $5,216 $6,232 

Accounts receivable, net

 15,076 15,118  16,829 15,118 

Inventories

 57,036 57,914  56,806 57,914 

Prepaid expenses and other current assets

 3,382 3,364  2,854 3,364 

Deferred income taxes

 1,248 1,222  1,260 1,222 

Total current assets

 80,665 83,850  82,965 83,850 

Property, plant and equipment, net

 
79,870
 
79,244
  
78,673
 
79,244
 

Goodwill

 23,622 23,622  23,622 23,622 

Intangible assets, net

 21,213 21,965  20,464 21,965 

Other non-current assets

 1,587 1,203  1,556 1,203 

Deferred income taxes, net

 4,943 4,894  4,933 4,894 

Total assets

 $211,900 $214,778  $212,213 $214,778 

LIABILITIES AND STOCKHOLDERS' EQUITY

          

Current liabilities:

          

Accounts payable

 $12,557 $14,874  $14,004 $14,874 

Accrued expenses

 4,836 6,835  5,101 6,835 

Total current liabilities

 17,393 21,709  19,105 21,709 

Long-term debt

 
42,000
 
43,000
  
38,000
 
43,000
 

Other non-current liabilities

 310 456  162 456 

Total liabilities

 59,703 65,165  57,267 65,165 

Stockholders' equity:

          

Common stock

 97 97  96 97 

Additional paid-in capital

 10,544 11,112  9,345 11,112 

Retained earnings

 141,698 138,347  145,794 138,347 

Accumulated other comprehensive income

 (142) 79  (251) 79 

Treasury stock

  (22) (38) (22)

Total stockholders' equity

 152,197 149,613  154,946 149,613 

Total liabilities and stockholders' equity

 $211,900 $214,778  $212,213 $214,778 

(1)
The condensed consolidated balance sheet as of September 30, 2014 has been prepared using information from the audited financial statements at that date.

   

The accompanying notes are an integral part of these condensed consolidated financial statements.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands, except per share data)


 Three months ended
December 31,
  Three months ended
March 31,
 Six months ended
March 31,
 

 2014 2013  2015 2014 2015 2014 

Net sales

 $53,044 $51,550  $55,404 $54,859 $108,448 $106,409 

Cost of sales

 27,189 25,488  28,149 27,699 55,338 53,187 

Gross profit

 25,855 26,062  27,255 27,160 53,110 53,222 

Operating expenses

              

Selling, general and administrative

 19,554 18,581  19,789 19,282 39,343 37,863 

Amortization of intangible assets

 732 584  728 652 1,460 1,236 

Income from operations

 5,569 6,897  6,738 7,226 12,307 14,123 

Interest and other expense, net

 297 318  273 350 570 668 

Income before provision for income taxes

 5,272 6,579  6,465 6,876 11,737 13,455 

Provision for income taxes

 1,921 2,444  2,369 2,552 4,290 4,996 

Net income

 $3,351 $4,135  $4,096 $4,324 $7,447 $8,459 

Other comprehensive income (loss)

 
 
 
 
  
 
 
 
 
 
 
 
 

Foreign currency translation adjustment, net of tax

 (221) 12  (109) 36 (330) 48 

Comprehensive income

 $3,130 $4,147  $3,987 $4,360 $7,117 $8,507 

Net income per common share

              

Basic

 $0.35 $0.42  $0.43 $0.44 $0.77 $0.86 

Diluted

 0.35 0.42  0.43 0.44 0.77 0.86 

Weighted average common shares outstanding

 
 
 
 
  
 
 
 
 
 
 
 
 

Basic

 9,653,113 9,837,631  9,622,051 9,843,590 9,637,753 9,840,578 

Dilutive effect of stock options

 6,894 10,028  4,874 9,021 5,884 9,524 

Diluted

 9,660,007 9,847,659  9,626,925 9,852,611 9,643,637 9,850,102 

   

The accompanying notes are an integral part of these condensed consolidated financial statements.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)


 Three months ended
December 31,
  Six months ended
March 31,
 

 2014 2013  2015 2014 

Cash flows from operating activities:

          

Net income

 $3,351 $4,135  $7,447 $8,459 

Adjustments to reconcile net income to net cash provided by operating activities:

          

Depreciation and amortization

 3,239 2,638  6,507 5,415 

Amortization of deferred financing fees

 36 46  67 92 

Losses on disposals of property, plant and equipment

 1 1  7 2 

Tax benefit from stock option exercises

  (51) (1) (51)

Deferred income taxes, net

 (75) 97  (77) 478 

Changes in assets and liabilities, net of effects of acquisitions:

          

Accounts receivable, net

 47 1,254  (1,706) (751)

Inventories

 907 (2,582) 1,137 (3,167)

Prepaid expenses and other current assets

 (11) (174) 517 356 

Other non-current assets

 60 (22) 81 (102)

Accounts payable

 (2,817) (322) (1,136) 574 

Accrued expenses

 (1,735) 460  (1,685) (494)

Other non-current liabilities

 4 16  10 (10)

Net cash provided by operating activities

 3,007 5,496  11,168 10,801 

Cash flows from investing activities:

          

Acquisitions of businesses

 (81) (6,227) (81) (9,139)

Purchases of property, plant and equipment

 (2,634) (3,077) (4,217) (6,437)

Net cash used in investing activities

 (2,715) (9,304) (4,298) (15,576)

Cash flows from financing activities:

          

Proceeds from debt

 1,000 7,500  2,000 12,000 

Payments on debt

 (2,000) (5,500) (7,000) (8,000)

Payments of deferred financing fees

 (420)   (420)  

Proceeds from issuances of common stock

 25 152  64 179 

Purchases of common stock for treasury

 (1,074) (521) (2,352) (1,430)

Tax benefit from stock option exercises

  51  1 51 

Net cash provided by (used in) financing activities

 (2,469) 1,682  (7,707) 2,800 

Effect of exchange rate changes on cash

 (132) (2) (179) 24 

Net decrease in cash

 (2,309) (2,128) (1,016) (1,951)

Cash at beginning of period

 6,232 8,235  6,232 8,235 

Cash at end of period

 $3,923 $6,107  $5,216 $6,284 

   

The accompanying notes are an integral part of these condensed consolidated financial statements.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(dollars in thousands, except per share data)

1. BASIS OF PRESENTATION

        Nutraceutical International Corporation and its subsidiaries (the "Company") is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, the Company markets and distributes branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. The Company's core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. The Company believes that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

        The Company manufactures and sells nutritional supplements and other natural products under numerous brands, includingSolaray®,KAL®,Nature's Life®,LifeTime®,Natural Balance®, NaturalCare®,Health from the Sun®,Pioneer®,Nutra BioGenesis™,Life-flo®,Organix South®,Heritage Store® andMonarch Nutraceuticals™.

        The Company owns neighborhood natural food markets, which operate under the trade namesThe Real Food Company™,Thom's Natural Foods™ andCornucopia Community Market™. The Company also owns health food stores, which operate under various trade names, includingFresh Vitamins™,Granola's™ andPeachtree Natural Foods®.

        In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments, consisting of normal recurring adjustments, to state fairly the consolidated financial position of the Company as of DecemberMarch 31, 2014,2015, the results of its operations for the three and six months ended DecemberMarch 31, 20142015 and 20132014 and its cash flows for the threesix months ended DecemberMarch 31, 20142015 and 2013,2014, in conformity with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information applied on a consistent basis. Results for the three and six months ended DecemberMarch 31, 20142015 are not necessarily indicative of the results to be expected for the full fiscal year.

        Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with US GAAP have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form 10-K for the fiscal year ended September 30, 2014, which was filed with the Securities and Exchange Commission on November 20, 2014.

Use of Estimates

        The preparation of these financial statements in conformity with US GAAP required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow moving,slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

1. BASIS OF PRESENTATION (Continued)

New Accounting Standards

        In May 2014, the Financial Accounting Standards Board ("FASB") issued authoritative guidance, which is included in Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers." This guidance provides a single, comprehensive revenue recognition model for all contracts with customers and requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This guidance is effective for the Company as of October 1, 2017. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.

        In April 2015, the FASB issued authoritative guidance, which is included in ASC 835, "Simplifying the Presentation of Debt Issuance Costs." This guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt. This guidance is effective for the Company as of October 1, 2016. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.

        The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any other new standards that it believes merit further discussion, and the Company expects that none would have a significant impact on its consolidated financial statements.

2. ACCOUNTS RECEIVABLE

        Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:


 December 31,
2014
 September 30,
2014
  March 31,
2015
 September 30,
2014
 

Accounts receivable

 $16,124 $16,352  $17,897 $16,352 

Less allowances

 (1,048) (1,234) (1,068) (1,234)

 $15,076 $15,118  $16,829 $15,118 

3. INVENTORIES

        Inventories were comprised of the following:


 December 31,
2014
 September 30,
2014
  March 31,
2015
 September 30,
2014
 

Raw materials

 $20,919 $20,559  $21,166 $20,559 

Work-in-process

 6,792 6,909  7,907 6,909 

Finished goods

 29,325 30,446  27,733 30,446 

 $57,036 $57,914  $56,806 $57,914 

4. ACQUISITIONS

        During the three months ended December 31, 2014, the Company made one acquisition of a business. On November 18, 2014, the Company acquired certain operating assets of Agape Health Products for $81 in cash.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

4. ACQUISITIONS (Continued)

        During the threesix months ended DecemberMarch 31, 2013,2015, the Company made threeone acquisition of a business. On November 18, 2014, the Company acquired certain operating assets of Agape Health Products for $81 in cash.

        During the six months ended March 31, 2014, the Company made four acquisitions of businesses. On October 16, 2013, the Company acquired certain operating assets of TCCD International, Inc. On November 25, 2013, the Company acquired certain operating assets of Green Luxury Brands, Inc. On December 19, 2013, the Company acquired certain operating assets of Twinlab Corporation. On January 15, 2014, the Company acquired certain operating assets of Peachtree Natural Foods, Inc. The aggregate purchase price of these acquisitions was $6,227$9,139 in cash.

        The Condensed Consolidated Statements of Operations and Comprehensive Income and the Condensed Consolidated Statements of Cash Flows presented herein include the activities of these acquired businesses from their respective dates of acquisition. The expected long-term sales and expense synergies of acquired businesses generally are not realized immediately following acquisition, as certain transition and integration matters must be completed.

        These acquisitions are in keeping with the Company's business strategy of consolidating the fragmented industry wherein which it competes. These acquisitions were accounted for using the acquisition method of accounting. Accordingly, the aggregate purchase price was assigned to the assets acquired based on their fair values at their respective dates of acquisition. The excess of aggregate purchase price over the fair values of the assets acquired was classified as goodwill. The goodwill relates to expected synergies from these acquisitions. The following reflects the final allocation of the aggregate purchase price for these acquisitions to the aggregate assets acquired:


 Fiscal 2015
Acquisition
 Fiscal 2014
Acquisitions
  Fiscal 2015
Acquisition
 Fiscal 2014
Acquisitions
 

Aggregate assets acquired:

          

Current assets

 $41 $1,072  $41 $1,857 

Goodwill

  2,822   4,399 

Intangible assets

 40 2,333  40 2,883 

 $81 $6,227  $81 $9,139 

        The fiscal 2015 and fiscal 2014 acquired intangible assets totaling $40 and $2,333,$2,883, respectively, related to trademarks, tradenames and customer relationships, and are being amortized over periods of two to twelve years for financial statement purposes. The fiscal 2015 and fiscal 2014 acquired intangible assets are expected to be deductible for tax purposes over fifteen years. Goodwill, which is not subject to amortization for financial statement purposes, of $2,822$4,399 for fiscal 2014, is expected to be deductible for tax purposes over fifteen years.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

5. GOODWILL AND INTANGIBLE ASSETS

        During the threesix months ended DecemberMarch 31, 2014,2015, there was no change in the carrying value of goodwill.

        The carrying amounts of intangible assets at DecemberMarch 31, 20142015 and September 30, 2014 were as follows:


 December 31, 2014 September 30, 2014  

 Weighted-
Average
Amortization
Period (Years)
 March 31, 2015 September 30, 2014  
 

 Gross
Carrying
Amount(1)
 Accumulated
Amortization(1)
 Net
Carrying
Amount
 Gross
Carrying
Amount(1)
 Accumulated
Amortization(1)
 Net
Carrying
Amount
 Gross
Carrying
Amount(1)
 Accumulated
Amortization(1)
 Net
Carrying
Amount
 Gross
Carrying
Amount(1)
 Accumulated
Amortization(1)
 Net
Carrying
Amount
 Weighted-
Average
Amortization
Period (Years)
 

Intangible assets subject to amortization:

                             

Trademarks/tradenames/patents

 $5,435 $(1,600)$3,835 $5,418 $(1,480)$3,938 11 $5,448 $(1,721)$3,727 $5,418 $(1,480)$3,938 11 

Customer relationships/distribution rights/ non-compete agreements

 16,557 (8,002) 8,555 16,517 (7,390) 9,127 7 16,557 (8,609) 7,948 16,517 (7,390) 9,127 7 

Developed software and technology

 772 (772)  772 (772)  5 772 (772)  772 (772)  5 

 22,764 (10,374) 12,390 22,707 (9,642) 13,065   22,777 (11,102) 11,675 22,707 (9,642) 13,065   

Intangible assets not subject to amortization:

 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Trademarks/tradenames/licenses

 8,823  8,823 8,900  8,900   8,789  8,789 8,900  8,900   

 $31,587 $(10,374)$21,213 $31,607 $(9,642)$21,965   $31,566 $(11,102)$20,464 $31,607 $(9,642)$21,965   

(1)
Amounts include the impact of foreign currency translation adjustments.

        Estimated future amortization expense related to the DecemberMarch 31, 20142015 net carrying amount of $12,390$11,675 for intangible assets subject to amortization is as follows:

Year Ending September 30,
 Estimated
Amortization
Expense
  Estimated
Amortization
Expense
 

2015(1)

 $2,133  $1,391 

2016

 2,156  2,174 

2017

 1,797  1,800 

2018

 1,607  1,610 

2019

 1,180  1,182 

Thereafter

 3,517  3,518 

 $12,390  $11,675 

(1)
Estimated amortization expense for the year ending September 30, 2015 includes only amortization to be recorded after DecemberMarch 31, 2014.2015.

Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

5. GOODWILL AND INTANGIBLE ASSETS (Continued)

        General and economic conditions may continue to impact retail and consumer demand, as well as the market price of the Company's common stock, and could negatively impact the Company's future operating performance, cash flow and/or stock price and could result in additional goodwill and/or intangible asset impairment charges being recorded in future periods. Also, the Company periodically reviews its brands to achieve marketing, sales and operational synergies. These reviews could result in brands being consolidated or discontinued and could result in intangible asset impairment charges being recorded in future periods. Such goodwill and/or intangible asset impairment charges could materially impact the Company's consolidated financial statements. The valuation of goodwill and intangible assets is subject to a high degree of judgment, uncertainty and complexity.

6. DEBT

        Debt was comprised of the following:


 December 31,
2014
 September 30,
2014
  March 31,
2015
 September 30,
2014
 

Long-term debt—revolving credit facility

 $42,000 $43,000  $38,000 $43,000 

        The carrying value of the Company's debt approximates fair value at DecemberMarch 31, 20142015 and September 30, 2014. Estimated fair values for debt have been determined based on borrowing rates currently available to the Company for bank loans with similar terms and maturities and are classified as Level 2 (significant observable inputs other than quoted prices) in the FASB's fair value hierarchy.

        On November 4, 2014, the Company amended its revolving credit facility (the "Credit Agreement"). The Credit Agreement extends the term of the credit facility to November 2019, increases the available credit borrowings to $100,000 with no automatic reductions and provides an accordion feature that can increase the available credit borrowings to $130,000, subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Credit Agreement continue to be Rabobank International and Wells Fargo. To date, the Company has not experienced any difficulties in accessing the available funds under the Credit Agreement. Deferred financing fees of $420 related to the Credit Agreement are being amortized over the term of the Credit Agreement.

        At DecemberMarch 31, 2014,2015, the Company had outstanding revolving credit borrowings of $42,000$38,000 under the Credit Agreement. Borrowings under the Credit Agreement are collateralized by substantially all assets of the Company. At the Company's election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a Base Rate plus a variable margin. Base Rate is the higher of: i)(i) the Prime Lending Rate, ii)(ii) the Federal Funds Rate plus 0.5% or iii)(iii) the one-month Eurodollar Rate multiplied by the Statutory Reserve Rate plus 1.0% (capitalized terms are defined in the Credit Agreement, a copy of which was filed with the Securities and Exchange Commission on November 5, 2014). At DecemberMarch 31, 2014,2015, the applicable weighted-average interest rate for outstanding borrowings was 1.74%1.77%. The Company is also required to pay a variable quarterly fee on the unused balance under the Credit Agreement. At DecemberMarch 31, 2014,2015, the applicable rate was 0.25%. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

6. DEBT (Continued)

three months. Accrued interest on Base Rate borrowings is payable quarterly. The Credit Agreement matures on November 4, 2019, and the Company is required to repay all principal and interest outstanding under the Credit Agreement on such date.

        The Credit Agreement contains restrictive covenants, including limitations on incurring other indebtedness and requirements that the Company maintain certain financial ratios. As of DecemberMarch 31, 2014,2015, the Company was in compliance with the restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring the Company to repay all amounts outstanding under the Credit Agreement.

7. SHARE PURCHASES

        During the three and six months ended DecemberMarch 31, 2014 and 2013,2015, the Company purchased 48,56268,463 and 21,705117,025 shares of common stock for an aggregate price of $1,074$1,278 and $521,$2,352, respectively. During the three and six months ended March 31, 2014, the Company purchased 35,415 and 57,120 shares of common stock for an aggregate price of $909 and $1,430, respectively. All of these shares of common stock held in treasury were retired prior to DecemberMarch 31 in the respective quarter of purchase.purchase, except at March 31, 2015 and 2014, the Company held 2,000 and 1,681 shares of common stock in treasury, respectively. As of DecemberMarch 31, 2014,2015, the Company was permitted to purchase up to 683,462614,999 additional shares under its approved purchase plan, with no expiration date or restrictions. The Company accounts for treasury shares using the cost method.

8. STOCK OPTIONS AND OTHER EQUITY AWARDS

        As of DecemberThe following table summarizes stock option activity during the six months ended March 31, 2014, the Company had 32,5002015:

 
 Number of
Options
 Weighted-
Average
Exercise
Price
 

Options outstanding and exercisable at September 30, 2014

  32,500 $14.22 

Exercised

  (600) 14.22 

Options outstanding and exercisable at March 31, 2015

  31,900  14.22 

        All stock options outstanding at a weighted average exercise price of $14.22. These stock optionsMarch 31, 2015 expire on September 30, 2015. There were no stock options exercised during the three months ended December 31, 2014.

        No options to purchase shares of common stock for the three and six months ended DecemberMarch 31, 20142015 and 20132014 were excluded from the computation of diluted earnings per share because none of the stock options were anti-dilutive.

        During the threesix months ended DecemberMarch 31, 2013,2015, the Company received proceeds of $9 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $1 and optionees realized an aggregate pre-tax gain of $3 from these stock option exercises. During the six months ended March 31, 2014, the Company received proceeds of $115 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $51 and optionees realized an aggregate pre-tax gain of $133 from these stock option exercises.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

8. STOCK OPTIONS AND OTHER EQUITY AWARDS (Continued)

        On January 28, 2013, stockholders approved the Nutraceutical International Corporation 2013 Long-Term Equity Incentive Plan (the "2013 Plan") and the reservation of 800,000 shares of the Company's common stock for issuance under the 2013 Plan. Equity awards available under the 2013 Plan include stock options, stock appreciation rights and stock awards. In conjunction with the Company's fiscal 2014 and fiscal 2013 incentive compensation (bonus) payments, 24,827 and 31,788 shares of the Company's common stock were issued, respectively. These non-cash stock awards were granted on December 11, 2014 and December 11, 2013 at an aggregate fair value of $504 and $775, respectively, with fair value being determined by the closing price of the Company's common stock on the grant date. These stock awards were registered, unrestricted and fully vested on the grant date. As of DecemberMarch 31, 2014,2015, 743,385 shares of the Company's common stock were available for issuance under the 2013 Plan.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

9. SEGMENTS

        Segment identification and selection is consistent with the management structure used by the Company's chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company's management structure and method of internal reporting, the Company has one operating segment. The Company's chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

        Net sales attributed to customers in the United States and foreign countries for the three and six months ended DecemberMarch 31, 20142015 and 20132014 were as follows:


 Three months ended
December 31,
  Three months ended
March 31,
 Six months ended
March 31,
 

 2014 2013  2015 2014 2015 2014 

United States

 $46,725 $45,323  $48,807 $46,962 $95,532 $92,285 

Foreign countries

 6,319 6,227  6,597 7,897 12,916 14,124 

 $53,044 $51,550  $55,404 $54,859 $108,448 $106,409 

        Certain net sales attributed to customers in the United States are sold to customers who in turn may sell such products to customers in foreign countries, while certain net sales attributed to customers in foreign countries are sold to customers who in turn may sell such products to customers in the United States.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

9. SEGMENTS (Continued)

        The Company's net sales by product group for the three and six months ended DecemberMarch 31, 20142015 and 20132014 were as follows:


 Three months ended
December 31,
  Three months ended
March 31,
 Six months ended
March 31,
 

 2014 2013  2015 2014 2015 2014 

Branded nutritional supplements and other natural products

 $47,877 $46,972  $49,883 $49,503 $97,760 $96,475 

Other(1)

 5,167 4,578  5,521 5,356 10,688 9,934 

 $53,044 $51,550  $55,404 $54,859 $108,448 $106,409 

(1)
Net sales for any other product or group of similar products are less than 10% of consolidated net sales.

Table of Contents

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

General

        The following discussion and analysis should be read in conjunction with the other sections of this report on Form 10-Q, including Part I, Item 1.

        We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. We believe that the consolidation and integration of these acquired businesses providesprovide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

        We manufacture and sell nutritional supplements and other natural products under numerous brands, includingSolaray®,KAL®,Nature's Life®,LifeTime®,Natural Balance®, NaturalCare®,Health from the Sun®,Pioneer®,Nutra BioGenesis™,Life-flo®,Organix South®,Heritage Store® andMonarch Nutraceuticals™.

        We own neighborhood natural food markets, which operate under the trade namesThe Real Food Company™,Thom's Natural Foods™ andCornucopia Community Market™. We also own health food stores, which operate under various trade names, includingFresh Vitamins™,Granola's™ andPeachtree Natural Foods®.

        We were formed in 1993 to effect a consolidation strategy in the fragmented vitamin, mineral, herbal and other nutritional supplements industry (the "VMS Industry"). Since our formation, we have completed numerous acquisitions of businesses in the VMS Industry. As a result of acquisitions, internal growth and cost management, we believe that we are well positioned to continue to capitalize on acquisition opportunities that arise in the VMS Industry.

Critical Accounting Policies

        The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America required us to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow moving,slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates. Our critical accounting policies include the following:

        Accounts Receivable—Provision is made for estimated bad debts based on periodic analysis of individual customer balances, including an evaluation of days sales outstanding, payment history, recent payment trends and perceived credit worthiness.creditworthiness. If general economic conditions and/or customer financial conditionconditions were to change, additional provisions for bad debts may be required, which could have a material impact on the consolidated financial statements.

        Inventories—Valuation adjustments are made for slow moving,slow-moving, obsolete and/or damaged inventory based on a periodic analysis of individual inventory items, including an evaluation of historical usage and/or movement, age, expiration date and general condition. If market demand and/or consumer preferences are less favorable than historical trends or future expectations, additional valuation


Table of Contents

adjustments for slow moving,slow-moving, obsolete and/or damaged inventory may be required, which could have a material impact on the consolidated financial statements.

        Property, Plant and Equipment—Depreciation and amortization expense is impacted by our judgments regarding the estimated useful lives of assets placed in service. If the estimated lives of assets are significantly less than expected, depreciation and amortization expense would be accelerated, which could have a material impact on the consolidated financial statements.

        We evaluate the recoverability of property, plant and equipment whenever events or circumstances indicate that the carrying amount of an asset group may not be recoverable. We measure recoverability of an asset group by comparison of its carrying amount to the future undiscounted cash flows the asset group is expected to generate. If an asset group is considered to be impaired, the difference between the carrying amount and the fair value of the impaired asset group is recognized as an impairment charge.

        Goodwill and Intangible Assets—Goodwill and intangible assets require estimates and judgments in determining the initial recognition and measurement, including factors and assumptions used in determining fair values and useful lives. Intangible assets with finite useful lives are amortized, while intangible assets with indefinite useful lives are not amortized. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill and indefinite-lived intangible assets are tested annually for impairment and when events or changes in circumstances indicate the carrying value may not be recoverable. The appropriateness of the indefinite-life classification of non-amortizable intangible assets is also reviewed as part of the annual testing or when circumstances warrant a change to a finite life. We perform our annual impairment testing as of September 30 each year, which is the last day of our fiscal year.

        A two-step process is used to test for goodwill impairment. The first step is to determine if there is an indication of impairment by comparing the estimated fair value of each reporting unit to its carrying value, including existing goodwill. Reporting unit fair values are estimated using market data as well as other factors. Goodwill is considered impaired if the carrying value of a reporting unit exceeds the estimated fair value. Upon an indication of impairment, a second step is performed to measure the amount of the impairment by comparing the implied fair value of the reporting unit's goodwill with its carrying value.

        Intangible assets with indefinite useful lives are tested for impairment at the individual tradename level by comparing the fair value of the indefinite-lived intangible asset to its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment charge is recognized. Fair values of indefinite-lived intangible assets are estimated using discounted cash flow models.

        Amortizable intangible assets are reviewed for recoverability by comparing an asset group's carrying amount to the future undiscounted cash flows the asset group is expected to generate. If an asset group is considered to be impaired, the difference between the carrying amount and the fair value of the impaired asset group is recorded.

        General and economic conditions may continue to impact retail and consumer demand, as well as the market price of our common stock, and could negatively impact our future operating performance, cash flow and/or stock price and could result in additional goodwill and/or intangible asset impairment charges being recorded in future periods. Also, we periodically review our brands to achieve marketing, sales and operational synergies. These reviews could result in additional brands being consolidated or discontinued and could result in additional intangible asset impairment charges being recorded in future periods. Such goodwill and/or intangible asset impairment charges could materially impact our consolidated financial statements. The valuation of goodwill and intangible assets is subject to a high degree of judgment, uncertainty and complexity.


Table of Contents

        Revenue Recognition—Revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the product has been shipped and the customer takes ownership and assumes the risk of loss; (3) the selling price is fixed or determinable; and (4) collection of the resulting receivable is reasonably assured. We believe that these criteria are satisfied upon shipment from our facilities or, in the case of our neighborhood natural food markets and health food stores, at the point of sale within these stores. Revenue is reduced by provisions for estimated customer returns and allowances, which are based on historical averages that have not varied significantly for the periods presented, as well as specific known claims, if any. No other significant deductions from revenue must be estimated at the point in time that revenue is recognized.

        Our estimates and judgments related to our critical accounting policies, including factors and assumptions considered in making these estimates and judgments, did not vary significantly for the periods presented and had no material impact on the consolidated financial statements as reported.

New Accounting Standards

        See Note 1 to the Condensed Consolidated Financial Statements for information regarding new accounting standards.

Results of Operations

        The following table sets forth certain consolidated statements of operations data as a percentage of net sales for the periods indicated:


 Three Months
Ended
December 31,
  Three Months
Ended
March 31,
 Six Months
Ended
March 31,
 

 2014 2013  2015 2014 2015 2014 

Net sales

 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

Cost of sales

 51.3% 49.4% 50.8% 50.5% 51.0% 50.0%

Gross profit

 48.7% 50.6% 49.2% 49.5% 49.0% 50.0%

Selling, general and administrative

 36.9% 36.1% 35.7% 35.1% 36.3% 35.6%

Amortization of intangible assets

 1.4% 1.2% 1.3% 1.2% 1.3% 1.2%

Income from operations

 10.4% 13.3% 12.2% 13.2% 11.4% 13.2%

Interest and other expense, net

 0.5% 0.6% 0.5% 0.6% 0.5% 0.6%

Income before provision for income taxes

 9.9% 12.7% 11.7% 12.6% 10.9% 12.6%

Provision for income taxes

 3.6% 4.7% 4.3% 4.7% 4.0% 4.7%

Net income

 6.3% 8.0% 7.4% 7.9% 6.9% 7.9%

Adjusted EBITDA(1)

 16.6% 18.5% 18.1% 18.2% 17.3% 18.4%

(1)
See "—Adjusted EBITDA."

Comparison of the Three Months Ended DecemberMarch 31, 20142015 to the Three Months Ended DecemberMarch 31, 20132014

        Net Sales.    Net sales increased by $1.4$0.5 million, or 2.9%1.0%, to $53.0$55.4 million for the three months ended DecemberMarch 31, 2014 ("first2015 (the "second quarter of fiscal 2015") from $51.6$54.9 million for the three months ended DecemberMarch 31, 2013 ("first2014 (the "second quarter of fiscal 2014"). Net sales of branded nutritional supplements and other natural products increased by $0.9$0.4 million, or 1.9%0.8%, to $47.9$49.9 million for the firstsecond quarter of fiscal 2015 compared to $47.0$49.5 million for the firstsecond quarter of fiscal 2014. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2014 and fiscal 2015 acquisitions and price increases


Table of Contents

contributions of the fiscal 2014 acquisitions,$1.1 million, partially offset by a decrease in sales volume of branded products to certain customers. The impact on net sales of branded products attributable to price changes was not material. Other net sales increased by $0.5 million, or 12.9%, to $5.1were $5.5 million for the firstsecond quarter of fiscal 2015 compared to $4.6and $5.4 million for the firstsecond quarter of fiscal 2014. The increase in other net sales was primarily related to the net sales contributions of the fiscal 2014 acquisitions.

        Gross Profit.    Gross profit was $25.9$27.3 million for the firstsecond quarter of fiscal 2015 and $26.1$27.2 million for the firstsecond quarter of fiscal 2014. As a percentage of net sales, gross profit was 48.7%49.2% for the firstsecond quarter of fiscal 2015 compared to 50.6%and 49.5% for the firstsecond quarter of fiscal 2014. This decrease in gross profit percentage was primarily related to an increase in manufacturing overhead costs.

        Selling, General and Administrative.    Selling, general and administrative expenses increased by $1.0$0.5 million, or 5.2%2.6%, to $19.6$19.8 million for the firstsecond quarter of fiscal 2015 from $18.6$19.3 million for the firstsecond quarter of fiscal 2014. As a percentage of net sales, selling, general and administrative expenses were 36.9%35.7% for the firstsecond quarter of fiscal 2015 and 36.1%35.1% for the firstsecond quarter of fiscal 2014. This increase in selling, general and administrative expenses was primarily attributable to operational and transition costs related to the fiscal 2014 acquisitions.

        Amortization of Intangible Assets.    Amortization of intangible assets was $0.7 million for both the firstsecond quarter of fiscal 2015 and $0.6 million for the firstsecond quarter of fiscal 2014. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.

        Interest and Other Expense, Net.    Net interest and other expense was $0.3 million for both the firstsecond quarter of fiscal 2015 and $0.4 million for the second quarter of fiscal 2014 and primarily consisted of interest expense on indebtedness under our revolving credit facility.

        Provision for Income Taxes.    Our effective tax rate was 36.4%36.6% for the firstsecond quarter of fiscal 2015 and 37.1% for the firstsecond quarter of fiscal 2014. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.

Comparison of the Six Months Ended March 31, 2015 to the Six Months Ended March 31, 2014

        Net Sales.    Net sales increased $2.0 million, or 1.9%, to $108.4 million for the six months ended March 31, 2015 from $106.4 million for the six months ended March 31, 2014. Net sales of branded nutritional supplements and other natural products increased by $1.3 million, or 1.3%, to $97.8 million for the six months ended March 31, 2015 from $96.5 million for the six months ended March 31, 2014. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2014 and fiscal 2015 acquisitions and, to a lesser extent, price increases of $0.8 million, partially offset by a decrease in sales volume of branded products to certain customers. Other net sales increased $0.7 million, or 7.6%, to $10.6 million for the six months ended March 31, 2015, compared to $9.9 million for the six months ended March 31, 2014. The increase in other net sales was primarily related to the net sales contributions of the fiscal 2014 acquisitions.

        Gross Profit.    Gross profit was $53.1 million for the six months ended March 31, 2015 and $53.2 million for the six months ended March 31, 2014. As a percentage of net sales, gross profit decreased to 49.0% for the six months ended March 31, 2015 from 50.0% for the six months ended March 31, 2014. This decrease in gross profit percentage was primarily related to an increase in manufacturing overhead costs.

        Selling, General and Administrative.    Selling, general and administrative expenses increased by $1.4 million, or 3.9%, to $39.3 million for the six months ended March 31, 2015 from $37.9 million for the six months ended March 31, 2014. As a percentage of net sales, selling, general and administrative expenses increased to 36.3% for the six months ended March 31, 2015, compared to 35.6% for the six months ended March 31, 2014. This increase in selling, general and administrative expenses was primarily attributable to operational and transition costs related to the fiscal 2014 acquisitions.


Table of Contents

        Amortization of Intangible Assets.    Amortization of intangible assets was $1.5 million for the six months ended March 31, 2015 and $1.2 million for the six months ended March 31, 2014. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.

        Interest and Other Expense, Net.    Net interest and other expense was $0.6 million for the six months ended March 31, 2015 and $0.7 million for the six months ended March 31, 2014 and primarily consisted of interest expense on indebtedness under our revolving credit facility.

        Provision for Income Taxes.    Our effective tax rate was 36.6% for the six months ended March 31, 2015 and 37.1% for the six months ended March 31, 2014. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.

Adjusted EBITDA

        Adjusted EBITDA (a non-GAAP measure) is defined in our performance measures as earnings before net interest and other expense, taxes, depreciation, amortization and goodwill and intangible asset impairments. Adjusted EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation. Furthermore, Adjusted EBITDA is not intended to be a substitute for cash flows from operating activities, as a measure of liquidity, or an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles. Our use of an EBITDA-based metric should be considered within the following context:


Table of Contents